FORM 3A - Director/Chief Executive Notice - Interests in Shares of Listed Corporation
 
Form Serial Number: DA20260106E00580
1. Date of relevant event: 31/12/2025
(dd/mm/yyyy)
2. Date when director became aware of the relevant event/ interest in the shares (if later):
(dd/mm/yyyy)
3. Stock code: 01513
4. Name of listed corporation: 丽珠医药集团股份有限公司 - H股 
5. Class of shares: A Shares 
6. Number of issued shares in class: 588,100,054
7. Name of director (English) as printed on HKID Card/Passport:
(Surname) ZHU
(Other names) BAOGUO
10. Name of director (Chinese): 朱保國 
11. Chinese Character Code as printed on HKID Card:
 
24. Details of relevant event:
  Brief description of relevant event Capacity in which shares were/are held Number of shares bought/sold or involved Currency of transaction On Exchange Off Exchange
Before relevant event After relevant event Highest price (per share) Average price (per share) Average consideration (per share) Consideration code
Long position 
1711Miscellaneous
Other (you must briefly describe the relevant event in the Supplementary Information box)
 
2201Interest of corporation controlled by you
 
2201Interest of corporation controlled by you
 		          
 
Short position 
 
 
 		            
 
25. Total shares in listed corporation immediately before the relevant event:
 Total number of sharesPercentage figure (%)
Long position255,513,95342.28
 
26. Total shares in listed corporation immediately after the relevant event:
 Total number of sharesPercentage figure (%)
Long position255,513,95343.45
 
27. Capacity in which interests disclosed in Box 26 are held:
Code describing capacityNumber of shares
2201Interest of corporation controlled by you
Long position255,513,953
 
28. Further information in derivative interests in listed corporation :
Derivatives code Exercise period (dd/mm/yyyy) Consideration - if derivatives granted by listed corporation Number of shares
  BeginsEndsCurrencyPrice for grantCurrencyExercise priceCurrencyPrice on assignment 
           
 
29. Further information in relation to interests of children under 18 and/or spouse:
Child/SpouseName of child/spouseNumber of shares
Spouse劉廣霞
Long position255,513,953
 
30. Further information in relation to interests of corporations controlled by Director:
Name of controlled corporationAddress and place of incorporationName of controlling person% controlDirect interest (Y/N)Number of shares
深圳市百業源投資有限公司深圳市南山區高新北區朗山路17號健康元藥業大廈314室 註冊成立地點：中國朱保國90.00N
Long position255,513,953
健康元藥業集團股份有限公司深圳市南山區高新北區朗山路17號健康元藥業大廈 註冊成立地點：中國深圳市百業源投資有限公司48.96N
Long position16,830,835
健康元藥業集團股份有限公司深圳市南山區高新北區朗山路17號健康元藥業大廈 註冊成立地點：中國深圳市百業源投資有限公司48.96Y
Long position238,683,118
深圳市海濱製藥有限公司中國深圳市鹽田區沙頭角沙鹽路2003號 註冊成立地點:中國健康元藥業集團股份有限公司100.00Y
Long position16,830,835
 
31. Further information in relation to interests held by Director jointly with another person:
Name of joint shareholderAddressNumber of shares
 
 
32. Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust:
Names of TrustAddressStatus codeNumber of shares
  
 
33. Further information from a party to an agreement under Section 317 (Please see Notes for further information required):
Names of other partiesAddressNumber of shares
 
Total number of shares in which a director is interested under sections 317 and 318
 
34. Supplementary information: 2025年12月31日，麗珠醫藥集團股份有限公司註銷了2024年12月25日至2025年11月7日期間已回購的A股股份共计16,193,259股。由於（1）朱保國先生直接持有深圳市百業源投資有限公司90%股權，其配偶劉廣霞女士直接持有深圳市百業源投資有限公司10%股權；（2）深圳市百業源投資有限公司直接持有健康元藥業集團股份有限公司48.96%股權；（3）健康元藥業集團股份有限公司直接及間接持有深圳市海濱製藥有限公司100%股權；而深圳市海濱製藥有限公司直接持有麗珠醫藥集團股份有限公司16,830,835股，健康元藥業集團股份有限公司直接持有及受托管理麗珠醫藥集團股份有限公司238,683,118股。註銷前，公司A股股本為604,293,313股，朱保國先生直接及間接持有的A股股數佔A股總股本數的42.28%。註銷後，公司A股股本為588,100,054股，朱保國先生直接及間接持有的股數佔A股總股本數的43.45%。朱保國先生持有的權益跨過了百分率整數，因此根據《證券及期貨條例》進行申報。
35. Log/Serial Number of the previous form:
36. Number of concert party document(s) under section 317 attached/uploaded:
Date of filing this Form 3A: 06/01/2026
(dd/mm/yyyy)